Clinical study for COVID-19 drug development
Implementation of a regulatory clinical phase for a new drug or repositioning for COVID-19: Phase I for toxicity, Phase IIa or IIb, measurement of efficacy and toxicity on a larger cohort, collection of PK/PD pharmacodynamic data.
It also applies for samples collections that require a specific protocol.
This service is designed for Biotech companies developing SARS-CoV-2 new drugs.
Materials to provide
- Details about the project
Further details on the project may be requested.
You will be able to exchange directly with the experts after filling in the form below.
- Study following the specifications validated with the Expert
Get started with your COVID-19 clinical study information request
Please answer the fields below to be contacted by our team of scientists